Menu Search
Equities

Kalbe Farma Tbk PT

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LCLA:STU

Kalbe Farma Tbk PT

Actions
  • Price (EUR)0.051
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-20.31%
  • Beta0.4773
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products, including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritional, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over-the-counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

  • Revenue in IDR (TTM)34.38tn
  • Net income in IDR3.49tn
  • Incorporated1967
  • Employees12.78k
  • Location
    Kalbe Farma Tbk PTGedung KALBE Let.Jend Suprato Kav. 4JAKARTA PUSAT 10510IndonesiaIDN
  • Phone+62 2 142873888
  • Fax+62 214256326
  • Websitehttps://www.kalbe.co.id
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.